603235 天新药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)6.44312.41214.71911.47920.853
总资产报酬率 ROA (%)5.05610.03312.1809.74116.302
投入资产回报率 ROIC (%)5.88611.68214.21511.24519.443

边际利润分析
销售毛利率 (%)41.07042.31242.01138.27237.225
营业利润率 (%)29.06430.07735.06129.87431.486
息税前利润/营业总收入 (%)31.05228.96029.96124.58827.560
净利润/营业总收入 (%)24.38725.22729.48625.28526.992

收益指标分析
经营活动净收益/利润总额(%)90.97495.16495.15192.31391.246
价值变动净收益/利润总额(%)1.4331.2670.9960.3671.511
营业外收支净额/利润总额(%)-0.032-0.127-0.3350.5220.009

偿债能力分析
流动比率 (X)3.5584.3785.2876.76610.175
速动比率 (X)2.7523.4824.1315.7288.663
资产负债率 (%)22.43320.57017.62216.84113.290
带息债务/全部投入资本 (%)3.4981.600-3.915-5.832-6.832
股东权益/带息债务 (%)2,591.8255,754.929-2,462.095-1,659.567-1,452.416
股东权益/负债合计 (%)345.776386.153467.476493.804652.428
利息保障倍数 (X)15.547-26.848-6.012-4.518-7.013

营运能力分析
应收账款周转天数 (天)41.18844.72942.09746.59346.227
存货周转天数 (天)146.352154.228150.130147.134109.004